Skip to main content

Table 1 Patient demographics and clinical characteristics (ITT-population: n = 77)

From: Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience

  Overall Starting dose Starting dose
320 mg/m2 ≤280 mg/m2
  n = 77 n = 37 n = 40 *
Female 14 (18.2 %) 6 (16.2 %) 8 (20.0 %)
Male 63 (81.1 %) 31 (83.3 %) 32 (80.0 %)
Median age in years (range) 67 (39–80) 66 (39–77) 70 (51–80)
≥70 y 32 (41.6 %) 12 (32.4 %) 20 (50.0 %)
ECOG PS    
0 35 (45.5 %) 18 (48.6 %) 17 (42.5 %)
1 42 (54.5 %) 19 (51.4 %) 23 (57.5 %)
Visceral involvement 46 (59.7 %) 23 (62.2 %) 23 (57.5 %)
Liver metastases 17 (22.1 %) 6 (16.2 %) 11 (27.5 %)
TFPC < 6 months 45 (58.4 %) 19 (51.4 %) 26 (65.0 %)
Mean Hb in g/dL§ 11.2 11.6 10.9
Hb < 10 g/dL§ 13 (16.9 %) 5 (13.5 %) 8 (20.0 %)
  1. ECOG: Eastern Cooperative Oncology Group; PS: performance status; TFPC: time from prior chemotherapy; Hb: hemoglobin
  2. *n(280 mg/m2) = 30; n(<280 mg/m2) = 10
  3. information missing for 4 patients in the 320 mg/m2 group and 8 patients in the ≤ 280 mg/m2 group
  4. information missing for 6 patients in the 320 mg/m2 group and 2 patients in the ≤ 280 mg/m2 group
  5. §information missing for 6 patients in the 320 mg/m2 group and 2 patients in the ≤ 280 mg/m2 group; ITT: intent-to-treat